Molecular Therapy · 2024 · 18 citations · 26 references
PharmacyOncologyPharmacologyAntibody EngineeringCell TherapyGene TherapyAntibody ConjugatesAntibody-drug ConjugatesCell Therapy ToxicityStem Cell Gene TherapyTargeted Cancer TherapyTargeted TherapyAntibody-drug Conjugate AntibodiesAntibody-drug Conjugate TherapyDrug Release MechanismsGene-targeted TherapyHematopoietic Stem Cell Transplant ConditioningTargeted ConditioningTransplant Conditioning ToxicityTransplantation
Stem cell gene therapy and hematopoietic stem cell transplantation (SCT) require conditioning to ablate the recipient's hematopoietic stem cells (HSCs) and create a niche for gene-corrected/donor HSCs. Conventional conditioning agents are non-specific, leading to off-target toxicities and resulting in significant morbidity and mortality. We developed tissue-specific anti-human CD45 antibody-drug conjugates (ADCs), using rat IgG2b anti-human CD45 antibody clones YTH24.5 and YTH54.12, conjugated to cytotoxic pyrrolobenzodiazepine (PBD) dimer payloads with cleavable (SG3249) or non-cleavable (SG3376) linkers. In vitro , these ADCs internalized to lysosomes for drug release, resulting in potent and specific killing of human CD45 + cells. In humanized NSG mice, the ADCs completely ablated human HSCs without toxicity to non-hematopoietic tissues, enabling successful engraftment of gene-modified autologous and allogeneic human HSCs. The ADCs also delayed leukemia onset and improved survival in CD45 + tumor models. These data provide proof of concept that conditioning with anti-human CD45-PBD ADCs allows engraftment of donor/gene-corrected HSCs with minimal toxicity to non-hematopoietic tissues. Our anti-CD45-PBDs or similar agents could potentially shift the paradigm in transplantation medicine that intensive chemo/radiotherapy is required for HSC engraftment after gene therapy and allogeneic SCT. Targeted conditioning both improve the safety and minimize late effects of these procedures, which would greatly increase their applicability.
26
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Haydar Frangoul, David Altshuler, Maria Domenica Cappellini et al. · New England Journal of Medicine · 2020 · 1.9K citations · Full text
Life Sciences, Genetics, Hematology +17
Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches
Agnieszka Czechowicz, Daniel Kraft, Irving L. Weissman et al. · Science · 2007 · 426 citations · Full text
Medicine, Hematology, Immunology +15
Outcomes Following Gene Therapy in Patients With Severe Wiskott-Aldrich Syndrome
Salima Hacein-Bey Abina, H. Bobby Gaspar, Johanna Blondeau et al. · JAMA · 2015 · 379 citations · Full text
Medicine, Hematology, Immunology +17